Welcome to our dedicated page for Meihua International Medical Technologies Co., Ltd. SEC filings (Ticker: MHUA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Meihua International Medical Technologies Co., Ltd. (MHUA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Meihua files annual reports on Form 20-F and current reports on Form 6-K under Commission File Number 001-41291, covering its operations as a manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China.
Through its Form 6-K filings, the company reports a range of material events. These include unaudited condensed consolidated financial statements and management’s discussion and analysis for interim periods, such as the six months ended June 30, 2025, which are incorporated by reference into its registration statements. Other 6-K filings describe private placements of ordinary shares to non-U.S. investors under Regulation S, including agreements to sell tens of millions of ordinary shares and subsequent closings, with stated uses of proceeds for working capital and general corporate purposes.
Corporate governance and capital structure changes are also documented in MHUA’s SEC filings. A Form 6-K dated November 18, 2025 details the results of an extraordinary general meeting where shareholders approved a one-for-one-hundred share consolidation, an increase in authorized share capital and the creation of a dual-class share structure with Class A and Class B ordinary shares, along with the adoption of a 2025 equity incentive plan. Another filing from October 2025 furnishes the notice and proxy materials for that extraordinary general meeting. A separate Form 6-K dated August 21, 2025 reports the resignation of the then chief executive officer, chief financial officer and a director, and the appointment of new executives and an independent director, including information on their roles and compensation arrangements.
Auditor changes and listing-related matters also appear in the filings. In a Form 6-K filed on January 7, 2026, Meihua discloses the dismissal of Kreit & Chiu CPA LLP and the appointment of Li CPA LLC as its independent registered public accounting firm for the year ended December 31, 2025, stating that there were no disagreements with the former auditor. Other filings reference the company’s registration statements on Forms F-3 and F-1 and the incorporation by reference of financial statements and XBRL data.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight the key points in each document, helping users quickly understand topics such as share structure changes, private placements, management transitions and auditor appointments. Real-time updates from EDGAR ensure that new Forms 20-F and 6-K, as well as exhibits like proxy statements and financial statements, are available as soon as they are filed. Users interested in MHUA can use this page to review the company’s regulatory history, analyze how it describes its financial condition and capital markets transactions, and monitor ongoing corporate and governance developments.
Meihua International Medical Technologies Co., Ltd. has filed a Form F-3 to register up to 520,000 Class A Ordinary Shares for resale by identified selling shareholders, from time to time after the effective date, pursuant to two share purchase agreements dated
The prospectus states the company will receive no proceeds from these resale transactions, the shares may be sold at fixed, market-related or negotiated prices, and the company will bear registration costs. The filing notes that trading in the Class A Ordinary Shares was suspended pending a Nasdaq Hearings Panel determination after a delisting notice; the last reported sale price was
Meihua International Medical Technologies has modified earlier lock-up restrictions on investors in its October 8 and December 5, 2025 private placements. On January 29, 2026, the company entered leak-out agreements that waive the prior 12‑month lock-up on these securities.
Instead of a full resale ban, each purchaser now agrees that, during the leak-out period, sales on any trading day will not exceed 15% of the average daily trading volume over the prior ten trading days, while the ordinary shares trade on specified U.S. exchanges. The leak-out terms apply once the securities are registered for resale or become sellable under Rule 144.
Meihua International Medical Technologies Co., Ltd. reports that investors in its recent private placements have agreed to lock-up restrictions on their shares. The company previously completed an October offering of 40,000,000 ordinary shares (or 400,000 Class A ordinary shares on a post reverse-split and post re-designation basis) for gross proceeds of $15.2 million, and a December offering of up to 120,000 Class A ordinary shares for gross proceeds of $1.32 million. On January 22, 2026, all purchasers from both offerings entered into a lock-up agreement, committing for 12 months after each closing not to sell, pledge, or otherwise dispose of their Meihua securities or seek registration of those securities without the company’s prior written consent.
Meihua International Medical Technologies Co., Ltd. filed an amended report to correct clerical errors in an earlier description of its October 2025 private placement. The company had agreed to sell 40,000,000 ordinary shares at a purchase price of $0.38 per share for gross proceeds of $15.2 million to several non-U.S. purchasers under Regulation S.
According to the updated disclosure, the company issued 24,000,000 ordinary shares to these purchasers on October 17, and on January 20, 2026 it issued the remaining 160,000 class A ordinary shares, par value $0.05 per share, after a 100:1 split and adoption of a dual-class structure, completing the October offering. The company reports 857,914 issued and outstanding class A ordinary shares as of January 20, 2026.
Meihua International Medical Technologies Co., Ltd. reported a change in its independent auditor. Effective December 26, 2025, the board and audit committee dismissed Kreit & Chiu CPA LLP and appointed Li CPA LLC (PCAOB ID: 7093) as the company’s independent registered public accounting firm for the year ended December 31, 2025.
The company states that Kreit & Chiu CPA’s audit reports for 2022, 2023, and 2024 contained no adverse opinions, disclaimers, or qualifications and that there were no disagreements or reportable events under SEC rules during those periods. Meihua also notes it did not previously consult Li CPA on accounting or auditing matters before this engagement. A confirming letter from Kreit & Chiu CPA has been filed as an exhibit.
Meihua International Medical Technologies completed a Regulation S private placement of 120,000 class A ordinary shares at $11 per share, raising gross proceeds of $1,320,000. The company plans to use the net proceeds for working capital and general corporate purposes.
The December investors are non-U.S. persons and made customary investment, business condition, and legal representations under the securities purchase agreement. The filing also notes that in October 2025 Meihua privately placed 40,000,000 ordinary shares at $0.38 per share for gross proceeds of $15.2 million, and that it currently has 697,914 issued and outstanding class A ordinary shares.
Meihua International Medical Technologies Co., Ltd. (MHUA) reported the results of an extraordinary general meeting held on November 8, 2025. Shareholders holding 38,358,424 of the 55,904,468 ordinary shares outstanding were present in person or by proxy, satisfying the quorum requirement.
Shareholders approved a share consolidation that changes the Company’s authorized share capital from USD50,000 divided into 80,000,000 ordinary shares and 20,000,000 preferred shares, each with a par value of USD0.0005, to USD50,000 divided into 800,000 ordinary shares and 200,000 preferred shares, each with a par value of USD0.05. The voting results on the resolutions showed a very high level of support, with the main proposal receiving 38,304,099 votes in favor, 34,500 against and 27 abstentions.
Meihua International Medical Technologies (MHUA) filed a Form 6-K announcing an extraordinary general meeting of shareholders to be held on November 3, 2025. The filing attaches the Notice of Extraordinary General Meeting and Proxy Statement as Exhibit 99.1 and a Proxy Card as Exhibit 99.2.
As a foreign private issuer, the Notice is not subject to SEC review. Shareholders are encouraged to read the Notice, which provides important details about the Company and the EGM. Documents are available on sec.gov and the Company’s IR site at http://ir.meihuamed.com/, or by written request to the Company’s Yangzhou address.
Meihua International Medical Technologies (MHUA) entered into a securities purchase agreement with certain non‑U.S. persons to sell up to 40,000,000 ordinary shares at $0.38 per share for gross proceeds of $15.2 million. The company states the shares were issued in reliance on Regulation S under the Securities Act.
The closing of the offering is subject to the satisfaction of all closing conditions in the SPA. Meihua currently intends to use the net proceeds for working capital and general corporate purposes. The SPA includes customary representations and covenants, including purchaser status as non‑U.S. persons, no undisclosed material adverse effect, and no legal proceedings that would affect completion.
Meihua International Medical Technologies Co., Ltd. (MHUA) furnished a Current Report on Form 6-K dated